Stock traders buy high volume call options on Sanofi (NASDAQ:SNY)
Sanofi Inc (NASDAQ:SNY – Get Rating) saw unusual options trading activity on Friday. Stock traders bought 3,211 call options on the company. This represents a 93% increase from the typical volume of 1,666 call options.
Sanofi Institutional Trading
A number of institutional investors and hedge funds have recently bought and sold shares of the company. GHP Investment Advisors Inc. acquired a new equity stake in Sanofi in the first quarter valued at approximately $26,000. Fairfield Bush & CO. bought a new equity stake in Sanofi during the first quarter for a value of approximately $26,000. Eagle Bay Advisors LLC purchased a new equity stake in Sanofi during the second quarter for approximately $28,000. Pinnacle Bancorp Inc. increased its position in Sanofi by 49.0% in the first quarter. Pinnacle Bancorp Inc. now owns 587 shares of the company worth $30,000 after acquiring 193 additional shares in the last quarter. Finally, Ahrens Investment Partners LLC bought a new position in Sanofi in the first quarter worth $31,000. 10.33% of the shares are currently held by hedge funds and other institutional investors.
Sanofi stock market performance
Shares of NASDAQ:SNY traded down $0.66 during Friday’s trading, hitting $38.47. 31,728 shares of the stock have traded, compared to its average volume of 2,093,357. The company has a quick ratio of 0.34, a current ratio of 1.29 and a leverage ratio of 0.22 . The company has a market capitalization of $97.52 billion, a price/earnings ratio of 12.76, a P/E/G ratio of 0.98 and a beta of 0.53. The company has a fifty-day moving average price of $43.81 and a two-hundred-day moving average price of $48.70. Sanofi has a 52-week low of $38.66 and a 52-week high of $58.10.
Sanofi (NASDAQ:SNY – Get Rating) last announced its results on Thursday, July 28. The company reported earnings per share (EPS) of $0.92 for the quarter, beating the consensus estimate of $0.85 by $0.07. The company posted revenue of $10.78 billion for the quarter, versus $10.32 billion expected by analysts. Sanofi posted a net margin of 16.60% and a return on equity of 25.99%. As a group, equity analysts expect Sanofi to post EPS of 4.14 for the current year.
Analyst upgrades and downgrades
Several brokerages have weighed in on SNY recently. TheStreet upgraded Sanofi’s shares from a “b-” to a “c+” rating in a Thursday, September 15 research note. StockNews.com upgraded Sanofi shares from a “buy” rating to a “strong buy” rating in a report on Sunday, August 14. JPMorgan Chase & Co. raised its price target on Sanofi shares from €105.00 ($107.14) to €115.00 ($117.35) in a Monday, August 1 report. Deutsche Bank Aktiengesellschaft lowered its price target on Sanofi shares from €90.00 ($91.84) to €85.00 ($86.73) and set a “hold” rating for the company in a report from Wednesday, September 7. Finally, Credit Suisse Group raised its price target on Sanofi shares from €105.00 ($107.14) to €110.00 ($112.24) and gave the company an “outperforming” rating. in a Friday July 22 research report. Four analysts gave the stock a hold rating, six issued a buy rating and one issued a strong buy rating for the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $105.38.
Sanofi Company Profile
(Get a rating)
Sanofi, together with its subsidiaries, is engaged in the research, development, manufacturing and marketing of therapeutic solutions in the United States, Europe and internationally. It operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology and rare blood disorders; diabetes medication; and cardiovascular and established prescription products.
This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Before you consider Sanofi, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Sanofi wasn’t on the list.
While Sanofi currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the five actions here